Healthcare Value Capital’s Fibrocell Science Inc. FCSC Stock Holding History

Healthcare Value Capital’s Portfolio FCSC Stock Details FCSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,185	Closed	-$39.3K	–	20
2017 Q1	$32K	Hold	3,185	–	–	0.05%	19
2016 Q4	$30K	Sell	3,185 -6,666	-68%	-$71.5K	0.03%	20
2016 Q3	$106K	Hold	9,851	–	–	0.17%	20
2016 Q2	$170K	Hold	9,851	–	–	0.21%	24
2016 Q1	$369K	Hold	9,851	–	–	0.54%	24
2015 Q4	$672K	Hold	9,851	–	–	1.11%	16
2015 Q3	$569K	Sell	9,851 -667	-6%	-$59K	0.81%	21
2015 Q2	$831K	Hold	10,518	–	–	0.87%	23
2015 Q1	$712K	Hold	10,518	–	–	0.78%	23
2014 Q4	$409K	Hold	10,518	–	–	0.75%	21
2014 Q3	$458K	Hold	10,518	–	–	0.44%	27
2014 Q2	$629K	Buy	10,518 +3,333	+46%	+$186K	0.53%	24
2014 Q1	$564K	Buy	+7,185	New	+$557K	0.37%	37

Other funds holding FCSC

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Healthcare Value Capital's FCSC Position: Q2 2017 in Review

Healthcare Value Capital sold out of Fibrocell Science Inc. (FCSC) in Q2 2017, closing a stake of 3,185 shares — an estimated $39.3K sold.

Healthcare Value Capital first reported a position in FCSC in Q1 2014 and held it in 13 quarters. The position peaked at $831K in Q2 2015. 29 funds tracked by Wall St. Rank hold FCSC as of Q2 2017.

Healthcare Value Capital reported no remaining Fibrocell Science Inc. position as of Q2 2017 after selling out during the quarter.
Healthcare Value Capital sold 3,185 Fibrocell Science Inc. shares in Q2 2017, an estimated $39.3K.
Healthcare Value Capital first reported a position in Fibrocell Science Inc. in Q1 2014 and held it in 13 quarters.
Healthcare Value Capital's Fibrocell Science Inc. position peaked at $831K in Q2 2015.
29 funds tracked by Wall St. Rank held Fibrocell Science Inc. as of Q2 2017.

Based on Healthcare Value Capital's 13F filing for Q2 2017, filed 10 Aug 2017.